Scholar Rock/$SRRK
1D1W1MYTD1Y5YMAX
About Scholar Rock
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
- Ticker
- $SRRK
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 289
- Headquarters
- Cambridge, United States
- Website
- www.scholarrock.com
Scholar Rock Metrics
BasicAdvanced
$6.9B
-
-$3.36
0.67
-
Price and volume
Market cap
$6.9B
Beta
0.67
52-week high
$58.49
52-week low
$27.07
Average daily volume
1M
Financial strength
Current ratio
7.021
Quick ratio
6.812
Long term debt to equity
77.829
Total debt to equity
77.829
Interest coverage (TTM)
-38.02%
Profitability
EBITDA (TTM)
-404.883
Management effectiveness
Return on assets (TTM)
-58.82%
Return on equity (TTM)
-167.77%
Valuation
Price to book
27.08
Price to tangible book (TTM)
27.08
Price to free cash flow (TTM)
-23.136
Free cash flow yield (TTM)
-4.32%
Free cash flow per share (TTM)
-2.443
Growth
Earnings per share change (TTM)
2.18%
3-year earnings per share growth (CAGR)
5.05%
What the Analysts think about Scholar Rock
Analyst ratings (Buy, Hold, Sell) for Scholar Rock stock.
Scholar Rock Financial Performance
Revenues and expenses
Scholar Rock Earnings Performance
Company profitability
Scholar Rock News
AllArticlesVideos
Scholar Rock Eyes Sept. 30 FDA Decision for SMA Drug Apitegromab
MarketBeat2 days ago
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire5 days ago
Scholar Rock drops Catalent facility from marketing application for muscle weakness drug
Reuters2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.